News
bioMérieux co-hosted a conference with the Embassy of France in the United States on May 14 titled, “Rising to the Challenge: United Against Antimicrobial Resistance.” The conference featured renowned speakers from various sectors, including government agencies, academia, and industry, who discussed the latest global policies and initiatives to tackle antimicrobial resistance (AMR). His Excellency Laurent Bili, French Ambassador to the United States and Alexandre Mérieux, bioMérieux Chairman of the Board of Directors, gave opening remarks.
Swipe to discover more
-
bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury
bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury (mTBI), including concussion. -
Diagnostic Stewardship: choosing the right test
Clinical labs are often faced with the challenge of needing to be better, faster, and more productive – while sometimes expected to do so with fewer resources and contending with supply chain issues. With the continued focus on value-based care as a main objective in healthcare, optimizing the utilization of diagnostic testing is more important than ever. -
bioMérieux Named Business of the Year by Utah Governor’s Office of Economic Opportunity
bioMérieux, a world leader in the field of in vitro diagnostics, has received the 2024 Business of the Year Award, presented by the Utah Governor’s Office of Economic Opportunity at One Utah Summit April 11-12, in Salt Lake City.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19